Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 27/06/2024 am IST			5-day change	1st Jan Change
4.11 ^USD	+4.31%		+4.58%	-24.17%

28/06	Goldman Sachs Downgrades Sagimet Biosciences to Hold From Buy, Price Target at $6	MT
06/06	Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial	MT

Sagimet Biosciences Inc. Appoints Anthony Rimac as Chief Financial Officer, Effective August 1, 2023

July 28, 2023 at 01:36 am IST

The Board of Directors of Sagimet Biosciences Inc. appointed Anthony Rimac to Chief Financial Officer of the Company to be effective August 1, 2023. Mr. Rimac has served as the Company?s Chief Operating Officer since April 2023.

Latest news about Sagimet Biosciences Inc.

Goldman Sachs Downgrades Sagimet Biosciences to Hold From Buy, Price Target at $6	28/06	MT
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial	06/06	MT
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data	06/06	MT
Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024	06/06	CI
Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	16/05	MT
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Sagimet Biosciences Names Thierry Chauche CFO	06/05	MT
Sagimet Biosciences Inc. Announces Executive Changes	06/05	CI
Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer	06/05	CI
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	02/05	MT
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04	CI
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04	CI
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04	CI
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	28/03	CI
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	26/03	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	25/03	MT
Sagimet Biosciences Inc. Announces Management Changes	25/03	CI
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	07/02	MT
Top Premarket Decliners	26/01	MT
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell	26/01	MT
Sagimet Biosciences Launches Public Offering of Series A Common Shares	24/01	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	23/01	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	23/01	MT
Sector Update: Health Care Stocks Advance Late Afternoon	23/01	MT

Chart Sagimet Biosciences Inc.

Duration

Period

More charts

Company Profile

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.42 USD

Average target price

35.8 USD

Spread / Average Target

+946.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SAGIMET BIOSCIENCES INC.	-24.17%	109M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research